(0.07%) 5 472.93 points
(0.11%) 39 157 points
(0.37%) 17 784 points
(0.10%) $80.91
(-3.66%) $2.66
(-0.76%) $2 313.00
(0.25%) $28.94
(3.64%) $1 022.30
(0.27%) $0.936
(0.66%) $10.67
(0.44%) $0.792
(-0.27%) $87.25
Live Chart Being Loaded With Signals
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases...
Stats | |
---|---|
今日成交量 | 13 976 |
平均成交量 | 134 290 |
市值 | 5.21M |
EPS | $-0.0902 ( Q1 | 2024-05-14 ) |
下一个收益日期 | ( $0 ) 2024-08-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-0.410 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0260 (0.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-19 | Frost Phillip Md Et Al | Sell | 129 802 | Common Stock |
2023-10-18 | Blank Andrew Scott | Buy | 12 434 | Stock Option (right to buy) |
2023-10-18 | Krasno Richard M | Buy | 12 434 | Stock Option (right to buy) |
2023-10-18 | Moyes Jay M | Buy | 12 434 | Stock Option (right to buy) |
2023-10-18 | Allen Jim L. | Buy | 12 434 | Stock Option (right to buy) |
INSIDER POWER |
---|
66.89 |
Last 98 transactions |
Buy: 2 428 796 | Sell: 415 660 |
音量 相关性
BioCardia Inc 相关性 - 货币/商品
BioCardia Inc 财务报表
Annual | 2023 |
营收: | $477 000 |
毛利润: | $66 000.00 (13.84 %) |
EPS: | $-0.550 |
FY | 2023 |
营收: | $477 000 |
毛利润: | $66 000.00 (13.84 %) |
EPS: | $-0.550 |
FY | 2022 |
营收: | $1.35M |
毛利润: | $-10.55M (-780.25 %) |
EPS: | $-0.670 |
FY | 2021 |
营收: | $1.02M |
毛利润: | $1.02M (100.00 %) |
EPS: | $-0.750 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
BioCardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。